Summary
Abbott Laboratories' 2018 10-K filing highlights a year of significant strategic growth and integration following major acquisitions in 2017, namely St. Jude Medical and Alere. The company's diversified healthcare portfolio, spanning Established Pharmaceuticals, Diagnostics, Nutritional Products, and Cardiovascular & Neuromodulation Products, demonstrated resilience and growth. Acquisitions have expanded Abbott's market leadership, particularly in diagnostics and medical devices, while strategic divestitures have refined its focus. The company successfully integrated acquired businesses, managing associated costs while driving operational improvements and investing in research and development to support future innovation. Abbott's financial health remains robust, supported by strong cash flow generation and a commitment to returning capital to shareholders through dividends and share repurchases, alongside a proactive approach to managing its debt.
Financial Highlights
52 data points| Revenue | $30.58B |
| Cost of Revenue | $12.71B |
| Gross Profit | $17.87B |
| R&D Expenses | $2.30B |
| SG&A Expenses | $9.74B |
| Operating Expenses | $26.93B |
| Operating Income | $3.65B |
| Interest Expense | $826.00M |
| Net Income | $2.37B |
| EPS (Basic) | $1.34 |
| EPS (Diluted) | $1.33 |
| Shares Outstanding (Basic) | 1.76B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1Abbott completed the strategic acquisitions of St. Jude Medical for approximately $23.6 billion and Alere for approximately $4.5 billion in 2017, significantly expanding its presence in cardiovascular devices and diagnostics, respectively.
- 2The company reported net sales of $30.6 billion for the year ended December 31, 2018, reflecting growth driven by acquisitions and organic volume increases across its key business segments.
- 3Abbott's Diagnostics segment saw substantial growth, with worldwide sales increasing 33.6% (excluding foreign exchange) in 2018, largely due to the integration of Alere and the continued rollout of the Alinity diagnostic systems.
- 4The Cardiovascular and Neuromodulation segment experienced sales growth of 4.9% (excluding foreign exchange) in 2018, driven by strong performance in Structural Heart, Electrophysiology, and Neuromodulation products.
- 5The company repurchased approximately $8.3 billion of debt in 2018, reducing its total debt to $19.6 billion, demonstrating a commitment to strengthening its balance sheet post-acquisitions.
- 6Abbott declared dividends of $1.16 per share in 2018, an increase of approximately 8% over the previous year, and increased its quarterly dividend by approximately 14% in December 2018.
- 7The company continued to invest in research and development, with R&D expenses totaling $2.3 billion in 2018, focusing on innovation across all its business segments, including the development of new diagnostic systems and advancements in medical devices.